MedPlus Health Services: Q3 FY26 Performance Driven by Strategic Store Expansion and Private Label Growth

MedPlus Health Services Limited has reported a robust performance for the third quarter of fiscal year 2026 (Q3 FY26), showcasing significant growth across key financial metrics. The company's consolidated revenue stood at 1,806.12 crore, marking a substantial 15.7% increase year-on-year. This growth was complemented by a strong operating EBITDA of 96.75 crore, up 21.1% from the previous year, and a profit after tax (PAT) of 57.79 crore, reflecting a 26.0% year-on-year surge. These figures underscore MedPlus's effective execution of its strategic initiatives and its ability to capitalize on market opportunities.

The pharmacy retail segment remained the primary growth driver, with revenue from pharmacy operations growing by 15.6% year-on-year. The segment's operating EBITDA reached 92.50 crore, representing a healthy 5.2% margin. The diagnostic segment also contributed positively, with revenue growing to 32.67 crore in Q3 FY26 from 27.47 crore in Q3 FY25, and an operating EBITDA of 5.07 crore, translating to a 15.5% margin. The company's focus on expanding its private label offerings has been a key factor, with private label sales constituting 22.2% of total revenues in Q3 FY26. This strategic emphasis on higher-margin private labels, particularly in pharma and FMCG, is enhancing overall profitability.

| Financial Summary (Q3 FY26) | |---|---| | Metric | Value (Crore) | | Consolidated Revenue | 1,806.12 | | Operating EBITDA | 96.75 | | Profit After Tax (PAT) | 57.79 | | Gross Margin | 472.44 | | Store Level Operating ROCE (12+ months) | 77.7% |

MedPlus's operational strategy is centered around a cluster-based expansion model, which has proven effective in deepening market penetration. The company added a net of 182 stores during the quarter, bringing its total network to 5,112 stores across 13 states and 1 union territory. This expansion is crucial for strengthening its omni-channel presence, enabling efficient 2-hour deliveries and leveraging existing stores as branding sites to reduce customer acquisition costs. The management has also tweaked its incentive structure for store staff, shifting focus to total sales growth rather than just private label sales, which has significantly contributed to a 10.5% same-store sales growth (SSSG) in the quarter. This adaptability in incentive programs highlights management's responsiveness to market dynamics and its commitment to driving comprehensive sales performance.

Strategic Pillars Driving Future Growth

MedPlus has outlined clear strategic pillars to sustain its growth trajectory. The first pillar focuses on deepening penetration in existing clusters and developing new ones, leveraging its established base. The second emphasizes enhancing its omni-channel leadership through its in-house technology platform, aiming to expand its addressable market and improve customer retention. The third pillar is dedicated to expanding the share of private label products, both in pharma and FMCG, to achieve higher margins and increase customer wallet share. These initiatives are supported by ongoing operational improvements, including the progressive operationalization of new warehouses, with 60-70% already functional and the rest expected to be online in the next two quarters.

Operational Efficiency and Capital Management

The company's focus on operational efficiency is evident in the performance of its older stores, those operational for more than 12 months. These stores reported a robust 12.4% store-level EBITDA margin and an impressive 77.7% Store Level Operating Return on Capital Employed (ROCE). This indicates that MedPlus's mature store network is highly profitable and capital-efficient. Furthermore, MedPlus has demonstrated disciplined capital management, with its net working capital reducing to 53 days in Q3 FY26. This improvement is partly attributed to the adoption of a franchisee model, which reduces the inventory carried on the company's books, and a mindful approach to inventory management at both store and warehouse levels. The company's strong cash and bank balance of 6,080 crore further solidifies its financial position.

Outlook and Management Commentary

Looking ahead, MedPlus management expressed confidence in maintaining the current gross margin levels and expects store expansion in FY27 to be similar to the current year's pace. While refraining from specific long-term guidance, the management highlighted the potential for continued growth in non-pharma private labels, given the vast addressable market and the company's ability to introduce new categories. The company is actively monitoring the competitive landscape, including the quick commerce segment, and adapting its offerings to remain competitive. Despite a one-off expense related to new Labour Code implementation, MedPlus's proactive approach to operational efficiency, strategic expansion, and private label growth positions it for sustained performance. The company's commitment to transparency and its ability to deliver on operational milestones instill confidence in its future trajectory.